person · Reporting owner
Shea Jacqueline Elizabeth
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INOVIO PHARMACEUTICALS, INC.INO · Entity 6589 | Director · Chief Executive Officer | May 20, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INOVIO PHARMACEUTICALS, INC.
Report date May 20, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 111,021 |
Ending reported balance
After 2026-05-20 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-20 · Exercise / conversion · Acquired 28,296 · Balance 123,327 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 84,888 restricted stock units was as follows: 28,296 shares vested on May 20, 2026; 28,296 shares will vest on May 20, 2027; 28,296 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Row 2 · 2026-05-20 · Tax withholding · Disposed 12,306 · Balance 111,021 F2: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 56,592 |
Reported balance
After 2026-05-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-20 · Exercise / conversion · Disposed 28,296 · Balance 56,592 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 84,888 restricted stock units was as follows: 28,296 shares vested on May 20, 2026; 28,296 shares will vest on May 20, 2027; 28,296 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 100,240 |
Reported balance
After 2026-05-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-20 · Grant · Acquired 100,240 · Balance 100,240 F5: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the restricted stock units granted on May 20, 2026 was as follows: 33,414 shares will vest on February 26, 2027; 33,413 shares will vest on February 26, 2028; and 33,413 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F6: The restricted stock units were approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the restricted stock units were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026. |
| Common Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.73 · Expires 2036-05-20 | Direct | 123,760 |
Reported balance
After 2026-05-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-20 · Grant · Acquired 123,760 · Balance 123,760 F3: The stock option grant was approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the stock options were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026. F4: The vesting schedule for the options granted on May 20, 2026 was as follows: 41,254 shares will vest on February 26, 2027; 41,253 shares will vest on February 26, 2028; 41,253 shares will vest on February 26, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 84,888 restricted stock units was as follows: 28,296 shares vested on May 20, 2026; 28,296 shares will vest on May 20, 2027; 28,296 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
F2: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein.
F3: The stock option grant was approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the stock options were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026.
F4: The vesting schedule for the options granted on May 20, 2026 was as follows: 41,254 shares will vest on February 26, 2027; 41,253 shares will vest on February 26, 2028; 41,253 shares will vest on February 26, 2029.
F5: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the restricted stock units granted on May 20, 2026 was as follows: 33,414 shares will vest on February 26, 2027; 33,413 shares will vest on February 26, 2028; and 33,413 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
F6: The restricted stock units were approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the restricted stock units were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 11, 2023 Filed Mar 13, 2023 21:07 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 59,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-23-000012 · wf-form4_167874165226829.xml · derivative · entry 3 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 59,737 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. On March 11, 2020, the reporting person was granted 179,211 restricted stock units, vesting as follows: 59,737 shares vested on March 11, 2021; 59,737 shares vested on March 11, 2022; and 59,737 shares vested on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. On March 11, 2020, the reporting person was granted 179,211 restricted stock units, vesting as follows: 59,737 shares vested on March 11, 2021; 59,737 shares vested on March 11, 2022; and 59,737 shares vested on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. On March 11, 2020, the reporting person was granted 179,211 restricted stock units, vesting as follows: 59,737 shares vested on March 11, 2021; 59,737 shares vested on March 11, 2022; and 59,737 shares vested on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 11, 2023 Filed Mar 13, 2023 21:07 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 25,980 | $1.13 | $29,357.40 |
DisclosureSEC source: 0001055726-23-000012 · wf-form4_167874165226829.xml · nonDerivative · entry 2 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,817 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
| March 11, 2023 Filed Mar 13, 2023 21:07 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 59,737 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-23-000012 · wf-form4_167874165226829.xml · nonDerivative · entry 1 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. On March 11, 2020, the reporting person was granted 179,211 restricted stock units, vesting as follows: 59,737 shares vested on March 11, 2021; 59,737 shares vested on March 11, 2022; and 59,737 shares vested on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 22:44 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 836,800 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001055726-23-000007 · wf-form4_167762425136925.xml · derivative · entry 7 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 836,800 Underlying: Common Stock · 836,800 shares Expires 2033-02-27 F5 · derivative.exercise_date: The vesting schedule for the 836,800 options is as follows: 209,200 shares vested on February 27, 2023; 209,200 shares will vest on February 26, 2024; 209,200 shares will vest on February 26, 2025; and 209,200 shares will vest on February 26, 2026. Read SEC document |
| February 26, 2023 Filed Feb 28, 2023 22:44 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 70,234 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-23-000007 · wf-form4_167762425136925.xml · derivative · entry 6 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,466 Underlying: Common Stock · 70,234 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2022, the reporting person was granted 210,700 restricted stock units, vesting as follows: 70,234 shares vested on February 26, 2023; 70,233 shares will vest on February 26, 2024; and 70,233 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2022, the reporting person was granted 210,700 restricted stock units, vesting as follows: 70,234 shares vested on February 26, 2023; 70,233 shares will vest on February 26, 2024; and 70,233 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2022, the reporting person was granted 210,700 restricted stock units, vesting as follows: 70,234 shares vested on February 26, 2023; 70,233 shares will vest on February 26, 2024; and 70,233 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2023 Filed Feb 28, 2023 22:44 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 22,544 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-23-000007 · wf-form4_167762425136925.xml · derivative · entry 5 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,544 Underlying: Common Stock · 22,544 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2021, the reporting person was granted 67,633 restricted stock units, vesting as follows: 22,545 shares vested on February 26, 2022; 22,544 shares vested on February 26, 2023; and 22,544 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2021, the reporting person was granted 67,633 restricted stock units, vesting as follows: 22,545 shares vested on February 26, 2022; 22,544 shares vested on February 26, 2023; and 22,544 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2021, the reporting person was granted 67,633 restricted stock units, vesting as follows: 22,545 shares vested on February 26, 2022; 22,544 shares vested on February 26, 2023; and 22,544 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2023 Filed Feb 28, 2023 22:44 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 32,485 | $1.28 | $41,580.80 |
DisclosureSEC source: 0001055726-23-000007 · wf-form4_167762425136925.xml · nonDerivative · entry 4 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,060 F4 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (3) herein. Read SEC document |
| February 26, 2023 Filed Feb 28, 2023 22:44 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 70,234 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-23-000007 · wf-form4_167762425136925.xml · nonDerivative · entry 3 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2022, the reporting person was granted 210,700 restricted stock units, vesting as follows: 70,234 shares vested on February 26, 2023; 70,233 shares will vest on February 26, 2024; and 70,233 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2023 Filed Feb 28, 2023 22:44 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 9,788 | $1.28 | $12,528.64 |
DisclosureSEC source: 0001055726-23-000007 · wf-form4_167762425136925.xml · nonDerivative · entry 2 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,311 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
| February 26, 2023 Filed Feb 28, 2023 22:44 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 22,544 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-23-000007 · wf-form4_167762425136925.xml · nonDerivative · entry 1 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2021, the reporting person was granted 67,633 restricted stock units, vesting as follows: 22,545 shares vested on February 26, 2022; 22,544 shares vested on February 26, 2023; and 22,544 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 10, 2022 Filed May 11, 2022 21:03 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 198,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-22-000035 · wf-form4_165230299527837.xml · derivative · entry 2 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,000 Underlying: Common Stock · 198,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 198,000 restricted stock units is as follows: 66,000 shares will vest on May 10, 2023; 66,000 shares will vest on May 10, 2024; 66,000 shares will vest on May 10, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 198,000 restricted stock units is as follows: 66,000 shares will vest on May 10, 2023; 66,000 shares will vest on May 10, 2024; 66,000 shares will vest on May 10, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 198,000 restricted stock units is as follows: 66,000 shares will vest on May 10, 2023; 66,000 shares will vest on May 10, 2024; 66,000 shares will vest on May 10, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 198,000 restricted stock units is as follows: 66,000 shares will vest on May 10, 2023; 66,000 shares will vest on May 10, 2024; 66,000 shares will vest on May 10, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 10, 2022 Filed May 11, 2022 21:03 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 309,400 | $0.00 Strike: $2.49 | $0.00 |
DisclosureSEC source: 0001055726-22-000035 · wf-form4_165230299527837.xml · derivative · entry 1 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,400 Underlying: Common Stock · 309,400 shares Expires 2032-05-10 F1 · derivative.exercise_date: The vesting schedule for the 309,400 options is as follows: 77,350 shares vested on May 10, 2022; 77,350 shares will vest on May 10, 2023; 77,350 shares will vest on May 10, 2024; 77,350 shares will vest on May 10, 2025. Read SEC document |
| March 25, 2022 Filed Mar 28, 2022 20:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 16,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-22-000031 · wf-form4_164849769330568.xml · derivative · entry 3 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 50,000 restricted stock units is as follows: 16,667 shares vested on March 25, 2020; 16,667 shares vested on March 25, 2021; 16,666 shares vested on March 25, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 50,000 restricted stock units is as follows: 16,667 shares vested on March 25, 2020; 16,667 shares vested on March 25, 2021; 16,666 shares vested on March 25, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 50,000 restricted stock units is as follows: 16,667 shares vested on March 25, 2020; 16,667 shares vested on March 25, 2021; 16,666 shares vested on March 25, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 50,000 restricted stock units is as follows: 16,667 shares vested on March 25, 2020; 16,667 shares vested on March 25, 2021; 16,666 shares vested on March 25, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 25, 2022 Filed Mar 28, 2022 20:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 7,247 | $3.63 | $26,306.61 |
DisclosureSEC source: 0001055726-22-000031 · wf-form4_164849769330568.xml · nonDerivative · entry 2 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,555 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
| March 25, 2022 Filed Mar 28, 2022 20:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 16,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-22-000031 · wf-form4_164849769330568.xml · nonDerivative · entry 1 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 50,000 restricted stock units is as follows: 16,667 shares vested on March 25, 2020; 16,667 shares vested on March 25, 2021; 16,666 shares vested on March 25, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 11, 2022 Filed Mar 14, 2022 20:46 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 59,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-22-000022 · wf-form4_164729057942435.xml · derivative · entry 3 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,737 Underlying: Common Stock · 59,737 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 179,211 restricted stock units is as follows: 59,737 shares vested on March 11, 2021; 59,737 shares vested on March 11, 2022; 59,737 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 179,211 restricted stock units is as follows: 59,737 shares vested on March 11, 2021; 59,737 shares vested on March 11, 2022; 59,737 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 179,211 restricted stock units is as follows: 59,737 shares vested on March 11, 2021; 59,737 shares vested on March 11, 2022; 59,737 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 179,211 restricted stock units is as follows: 59,737 shares vested on March 11, 2021; 59,737 shares vested on March 11, 2022; 59,737 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 11, 2022 Filed Mar 14, 2022 20:46 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 25,974 | $3.22 | $83,636.28 |
DisclosureSEC source: 0001055726-22-000022 · wf-form4_164729057942435.xml · nonDerivative · entry 2 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,136 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
| March 11, 2022 Filed Mar 14, 2022 20:46 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 59,737 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-22-000022 · wf-form4_164729057942435.xml · nonDerivative · entry 1 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,110 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 179,211 restricted stock units is as follows: 59,737 shares vested on March 11, 2021; 59,737 shares vested on March 11, 2022; 59,737 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 23:46 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 210,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-22-000010 · wf-form4_164617838486383.xml · derivative · entry 5 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,700 Underlying: Common Stock · 210,700 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 210,700 restricted stock units is as follows: 70,234 shares will vest on February 26, 2023; 70,233 shares will vest on February 26, 2024; 70,233 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F4 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 210,700 restricted stock units is as follows: 70,234 shares will vest on February 26, 2023; 70,233 shares will vest on February 26, 2024; 70,233 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 210,700 restricted stock units is as follows: 70,234 shares will vest on February 26, 2023; 70,233 shares will vest on February 26, 2024; 70,233 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 210,700 restricted stock units is as follows: 70,234 shares will vest on February 26, 2023; 70,233 shares will vest on February 26, 2024; 70,233 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 23:46 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 282,300 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001055726-22-000010 · wf-form4_164617838486383.xml · derivative · entry 4 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,300 Underlying: Common Stock · 282,300 shares Expires 2032-02-26 F3 · derivative.exercise_date: The vesting schedule for the 282,300 options is as follows: 70,575 shares vested on February 26, 2022; 70,575 shares will vest on February 26, 2023; 70,575 shares will vest on February 26, 2024; 70,575 shares will vest on February 26, 2025. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 23:46 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 22,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-22-000010 · wf-form4_164617838486383.xml · derivative · entry 3 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,088 Underlying: Common Stock · 22,545 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 67,633 restricted stock units is as follows: 22,545 shares vested on February 26, 2022; 22,544 shares will vest on February 26, 2023; 22,544 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 67,633 restricted stock units is as follows: 22,545 shares vested on February 26, 2022; 22,544 shares will vest on February 26, 2023; 22,544 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 67,633 restricted stock units is as follows: 22,545 shares vested on February 26, 2022; 22,544 shares will vest on February 26, 2023; 22,544 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 67,633 restricted stock units is as follows: 22,545 shares vested on February 26, 2022; 22,544 shares will vest on February 26, 2023; 22,544 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 23:46 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 10,764 | $3.22 | $34,660.08 |
DisclosureSEC source: 0001055726-22-000010 · wf-form4_164617838486383.xml · nonDerivative · entry 2 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,373 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 23:46 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 22,545 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-22-000010 · wf-form4_164617838486383.xml · nonDerivative · entry 1 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 67,633 restricted stock units is as follows: 22,545 shares vested on February 26, 2022; 22,544 shares will vest on February 26, 2023; 22,544 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 20:26 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 38,535 | $10.01 | $385,735.35 |
DisclosureSEC source: 0001055726-21-000052 · wf-form4_162344318899072.xml · nonDerivative · entry 1 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,592 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: These transactions were executed in multiple trades at prices ranging from $10.00 to $10.06, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| March 26, 2021 Filed Mar 26, 2021 20:10 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 4,710 | $8.97 | $42,248.70 |
DisclosureSEC source: 0001055726-21-000034 · wf-form4_161678939086989.xml · nonDerivative · entry 3 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,127 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 20:10 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-21-000034 · wf-form4_161678939086989.xml · derivative · entry 4 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,666 Underlying: Common Stock · 16,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 50,000 restricted stock units is as follows: 16,667 shares vested on March 25, 2020; 16,667 shares vested on March 25, 2021; 16,666 shares will vest on March 25, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 50,000 restricted stock units is as follows: 16,667 shares vested on March 25, 2020; 16,667 shares vested on March 25, 2021; 16,666 shares will vest on March 25, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 50,000 restricted stock units is as follows: 16,667 shares vested on March 25, 2020; 16,667 shares vested on March 25, 2021; 16,666 shares will vest on March 25, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 50,000 restricted stock units is as follows: 16,667 shares vested on March 25, 2020; 16,667 shares vested on March 25, 2021; 16,666 shares will vest on March 25, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 20:10 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 7,247 | $9.06 | $65,657.82 |
DisclosureSEC source: 0001055726-21-000034 · wf-form4_161678939086989.xml · nonDerivative · entry 2 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,837 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 20:10 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 16,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-21-000034 · wf-form4_161678939086989.xml · nonDerivative · entry 1 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,084 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 50,000 restricted stock units is as follows: 16,667 shares vested on March 25, 2020; 16,667 shares vested on March 25, 2021; 16,666 shares will vest on March 25, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 12, 2021 Filed Mar 12, 2021 23:32 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 16,881 | $10.06 | $169,822.86 |
DisclosureSEC source: 0001055726-21-000023 · wf-form4_161559192268345.xml · nonDerivative · entry 3 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,417 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Reporting person intends to use the proceeds of this sale to pay taxes resulting from the recent vesting of Restricted Stock Units granted by the issuer. F4 · price: These transactions were executed in multiple trades at prices ranging from $9.96 to $10.18, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 23:32 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 59,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-21-000023 · wf-form4_161559192268345.xml · derivative · entry 4 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,474 Underlying: Common Stock · 59,737 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 179,211 restricted stock units is as follows: 59,737 shares vested on March 11, 2021; 59,737 shares will vest on March 11, 2022; 59,737 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 179,211 restricted stock units is as follows: 59,737 shares vested on March 11, 2021; 59,737 shares will vest on March 11, 2022; 59,737 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 179,211 restricted stock units is as follows: 59,737 shares vested on March 11, 2021; 59,737 shares will vest on March 11, 2022; 59,737 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 179,211 restricted stock units is as follows: 59,737 shares vested on March 11, 2021; 59,737 shares will vest on March 11, 2022; 59,737 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 23:32 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 25,974 | $10.57 | $274,545.18 |
DisclosureSEC source: 0001055726-21-000023 · wf-form4_161559192268345.xml · nonDerivative · entry 2 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,298 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 23:32 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 59,737 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-21-000023 · wf-form4_161559192268345.xml · nonDerivative · entry 1 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 179,211 restricted stock units is as follows: 59,737 shares vested on March 11, 2021; 59,737 shares will vest on March 11, 2022; 59,737 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2021 Filed Feb 27, 2021 00:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 67,633 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-21-000011 · wf-form4_161438428463289.xml · derivative · entry 2 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,633 Underlying: Common Stock · 67,633 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 67,633 restricted stock units is as follows: 22,544 shares will vest on February 26, 2022; 22,544 shares will vest on February 26, 2023; 22,545 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 67,633 restricted stock units is as follows: 22,544 shares will vest on February 26, 2022; 22,544 shares will vest on February 26, 2023; 22,545 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 67,633 restricted stock units is as follows: 22,544 shares will vest on February 26, 2022; 22,544 shares will vest on February 26, 2023; 22,545 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2021 Filed Feb 27, 2021 00:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 104,833 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001055726-21-000011 · wf-form4_161438428463289.xml · derivative · entry 1 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,833 Underlying: Common Stock · 104,833 shares Expires 2031-02-26 F1 · derivative.exercise_date: The vesting schedule for the 104,833 options is as follows: 26,208 shares vested on February 26, 2021; 26,208 shares will vest on February 26, 2022; 26,208 shares will vest on February 26, 2023; 26,209 shares will vest on February 26, 2024. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:12 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock Option · Derivative | 22,376 | $0.00 Strike: $3.62 | $0.00 |
DisclosureSEC source: 0001055726-21-000007 · wf-form4_161239754472771.xml · derivative · entry 4 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 22,376 shares Expires 2029-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:12 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 5,960 | $15.00 | $89,400.00 |
DisclosureSEC source: 0001055726-21-000007 · wf-form4_161239754472771.xml · nonDerivative · entry 3 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,535 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: These transactions were executed in multiple trades at prices ranging from $15.00 to $15.07, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:12 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 22,376 | $15.06 | $336,982.56 |
DisclosureSEC source: 0001055726-21-000007 · wf-form4_161239754472771.xml · nonDerivative · entry 2 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,495 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: These transactions were executed in multiple trades at prices ranging from $15.00 to $15.32, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:12 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 22,376 | $3.62 | $81,001.12 |
DisclosureSEC source: 0001055726-21-000007 · wf-form4_161239754472771.xml · nonDerivative · entry 1 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2021 Filed Jan 30, 2021 00:03 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock Option · Derivative | 55,248 | $0.00 Strike: $3.62 | $0.00 |
DisclosureSEC source: 0001055726-21-000005 · wf-form4_161196497789987.xml · derivative · entry 7 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,376 Underlying: Common Stock · 55,248 shares Expires 2029-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2021 Filed Jan 30, 2021 00:03 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 16,713 | $12.04 | $201,224.52 |
DisclosureSEC source: 0001055726-21-000005 · wf-form4_161196497789987.xml · nonDerivative · entry 5 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,495 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: These transactions were executed in multiple trades at prices ranging from $12.00 to $12.10, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| January 28, 2021 Filed Jan 30, 2021 00:03 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 55,248 | $3.62 | $199,997.76 |
DisclosureSEC source: 0001055726-21-000005 · wf-form4_161196497789987.xml · nonDerivative · entry 4 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2021 Filed Jan 30, 2021 00:03 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock Option · Derivative | 22,376 | $0.00 Strike: $3.62 | $0.00 |
DisclosureSEC source: 0001055726-21-000005 · wf-form4_161196497789987.xml · derivative · entry 6 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,624 Underlying: Common Stock · 22,376 shares Expires 2029-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2021 Filed Jan 30, 2021 00:03 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 5,960 | $12.04 | $71,758.40 |
DisclosureSEC source: 0001055726-21-000005 · wf-form4_161196497789987.xml · nonDerivative · entry 3 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,960 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: These transactions were executed in multiple trades at prices ranging from $12.00 to $12.07, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| January 27, 2021 Filed Jan 30, 2021 00:03 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 22,376 | $12.01 | $268,735.76 |
DisclosureSEC source: 0001055726-21-000005 · wf-form4_161196497789987.xml · nonDerivative · entry 2 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,920 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: These transactions were executed in multiple trades at prices ranging from $12.00 to $12.09, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| January 27, 2021 Filed Jan 30, 2021 00:03 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 22,376 | $3.62 | $81,001.12 |
DisclosureSEC source: 0001055726-21-000005 · wf-form4_161196497789987.xml · nonDerivative · entry 1 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,296 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 25, 2020 Filed Mar 26, 2020 20:10 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-20-000019 · wf-form4_158525343157103.xml · derivative · entry 3 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,333 Underlying: Common Stock · 16,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 50,000 restricted stock units is as follows: 16,667 shares vested on March 25, 2020; 16,667 shares will vest on March 25, 2021; 16,666 shares will vest on March 25, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 50,000 restricted stock units is as follows: 16,667 shares vested on March 25, 2020; 16,667 shares will vest on March 25, 2021; 16,666 shares will vest on March 25, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 50,000 restricted stock units is as follows: 16,667 shares vested on March 25, 2020; 16,667 shares will vest on March 25, 2021; 16,666 shares will vest on March 25, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 50,000 restricted stock units is as follows: 16,667 shares vested on March 25, 2020; 16,667 shares will vest on March 25, 2021; 16,666 shares will vest on March 25, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 25, 2020 Filed Mar 26, 2020 20:10 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 4,747 | $6.68 | $31,709.96 |
DisclosureSEC source: 0001055726-20-000019 · wf-form4_158525343157103.xml · nonDerivative · entry 2 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,920 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
| March 25, 2020 Filed Mar 26, 2020 20:10 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 16,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-20-000019 · wf-form4_158525343157103.xml · nonDerivative · entry 1 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 50,000 restricted stock units is as follows: 16,667 shares vested on March 25, 2020; 16,667 shares will vest on March 25, 2021; 16,666 shares will vest on March 25, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 11, 2020 Filed Mar 12, 2020 20:44 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 179,211 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-20-000016 · wf-form4_158404586490604.xml · derivative · entry 1 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,211 Underlying: Common Stock · 179,211 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 179,211 restricted stock units is as follows: 59,737 shares will vest on March 11, 2021; 59,737 shares will vest on March 11, 2022; 59,737 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 179,211 restricted stock units is as follows: 59,737 shares will vest on March 11, 2021; 59,737 shares will vest on March 11, 2022; 59,737 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 179,211 restricted stock units is as follows: 59,737 shares will vest on March 11, 2021; 59,737 shares will vest on March 11, 2022; 59,737 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 20:23 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 200,000 | $0.00 Strike: $3.62 | $0.00 |
DisclosureSEC source: 0001055726-19-000025 · wf-form4_155371816885809.xml · derivative · entry 2 Shea Jacqueline Elizabeth · CIK 0001771498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-03-25 F2 · derivative.exercise_date: The vesting schedule for the 200,000 options is as follows: 50,000 shares vested on March 25, 2019; 50,000 shares will vest on March 25, 2020; 50,000 shares will vest on March 25, 2021; 50,000 shares will vest on March 25, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.